Bristol-Myers Squibb Co. (NYSE: BMY) is 2.59% higher on its value in year-to-date trading and has touched a low of $39.35 and a high of $55.29 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BMY stock was last observed hovering at around $51.92 in the last trading session, with the day’s gains setting it 0.72%.
Currently trading at $52.64, the stock is -0.56% and 3.61% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 8.53 million and changing 1.39% at the moment leaves the stock 9.96% off its SMA200. BMY registered -0.62% loss for a year compared to 6-month gain of 17.92%. The firm has a 50-day simple moving average (SMA 50) of $50.8068 and a 200-day simple moving average (SMA200) of $47.8708.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 3.40% loss in the last 1 month and extending the period to 3 months gives it a 7.32%, and is 1.00% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.77% over the week and 2.12% over the month.
Bristol-Myers Squibb Co. (BMY) has around 34100 employees, a market worth around $106.72B and $46.51B in sales. Fwd P/E is 7.55. Profit margin for the company is -14.06%. Distance from 52-week low is 33.77% and -4.79% from its 52-week high. The company has generated returns on investments over the last 12 months (-9.72%).
with sales reaching $11.28B over the same period.The EPS is expected to shrink by -90.63% this year, but quarterly earnings will post 11.30% year-over-year. Quarterly sales are estimated to grow 12.90% in year-over-year returns.
Bristol-Myers Squibb Co. (BMY) Top Institutional Holders
2813.0 institutions hold shares in Bristol-Myers Squibb Co. (BMY), with institutional investors hold 79.47% of the company’s shares. The shares outstanding are 2.03B, and float is at 2.03B with Short Float at 1.11%. Institutions hold 79.38% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 186.57 million shares valued at $7.75 billion. The investor’s holdings represent 9.2225% of the BMY Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 158.66 million shares valued at $6.59 billion to account for 7.8428 of the shares outstanding. The other top investors are STATE STREET CORP which holds 91.45 million shares representing 4.5203% and valued at over $3.8 billion, while JPMORGAN CHASE & CO holds 3.6891 of the shares totaling 74.63 million with a market value of $3.1 billion.
Bristol-Myers Squibb Co. (BMY) Insider Activity
The most recent transaction is an insider purchase by BOERNER CHRISTOPHER S., the company’s Chief Executive Officer. SEC filings show that BOERNER CHRISTOPHER S. bought 2,000 shares of the company’s common stock on Dec 05 ’23 at a price of $49.78 per share for a total of $99560.0. Following the purchase, the insider now owns 82672.0 shares.
Bristol-Myers Squibb Co. disclosed in a document filed with the SEC on Nov 28 ’23 that BOERNER CHRISTOPHER S. (Chief Executive Officer) bought a total of 3,071 shares of the company’s common stock. The trade occurred on Nov 28 ’23 and was made at $48.86 per share for $0.15 million. Following the transaction, the insider now directly holds 79384.0 shares of the BMY stock.
Still, SEC filings show that on Nov 20 ’23, Samuels Theodore R. II (Director) acquired 8,500 shares at an average price of $49.81 for $0.42 million. The insider now directly holds 35,500 shares of Bristol-Myers Squibb Co. (BMY).
